CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed
Drug / intervention
decitabinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00019825
NCT00019825Phase 1Completed
CompareCT.gov

Phase I Study of Decitabine Mediated Induction of Tumor Antigen and Tumor Suppressor Gene Expression in Lung Cancer Patients

National Cancer Institute (NCI)·interventional·Posted Jan 27, 2003·Updated Apr 29, 2015

In Brief

A Phase 1 clinical trial evaluating decitabine for Esophageal Cancer and 3 related conditions. Completed, across 2 sites.

Detailed Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of decitabine in treating patients who have unresectable lung or esophageal cancer or malignant mesothelioma of the pleura.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Cancer, Lung Cancer, Malignant Mesothelioma, Metastatic Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2003
Enrollment StartOct 1, 1999
TodayJul 2, 2026
Posted 23.4 years ago

Interventions

decitabinedrug